CoChat
Sign Up
Cited by 209

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials

Wessels, Alette M., Tariot, Pierre N., Zimmer, Jennifer A., Selzler, Katherine J., Bragg, Sonja M., Andersen, Scott W., Landry, John, Krull, James H., Downing, AnnCatherine M., Willis, Brian A., Shcherbinin, Sergey, Mullen, Jamie, Barker, Peter, Schumi, Jennifer, Shering, Craig, Matthews, Brandy R., Stern, Robert A., Vellas, Bruno, Cohen, Sharon, MacSweeney, Emer, Boada, Mercè, Sims, John R.·2020·JAMA Neurology
DOI 10.1001/jamaneurol.2019.3988PMC PMC6902191
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2019.3988

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In trials, weight loss was greatest in individuals with a higher BMI.

    “In trials, weight loss was greatest in individuals with a higher BMI”

    From BACE1: More than just a β‐secretase (2022) · cites this paper as [188]

  • A greater number of individuals observed a weight loss of at least 7% when taking Lanabecestat than placebo, with mean weight loss at −1.9 kg for 50-mg Lanabecestat group compared with 0 for placebo.

    “A greater number of individuals observed a weight loss of at least 7% when taking Lanabecestat, than individuals taking the placebo, with mean weight loss at −1.9 kg for the 50‐mg Lanabecestat group compared with 0 for the placebo group.”

    From BACE1: More than just a β‐secretase (2022) · cites this paper as [188]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 22

  1. Reitz, 2011, Epidemiology of Alzheimer disease., Nat Rev Neurol, 7, 137, 10.1038/nrneurol.2011.2 · DOI · Paper page
  2. Masters, 2015, Alzheimer’s disease., Nat Rev Dis Primers, 1, 15056, 10.1038/nrdp.2015.56 · DOI · Paper page
  3. Govaerts, 2007, Pathogenesis of Alzheimer’s disease: molecular and cellular mechanisms [in French]., Rev Med Liege, 62, 209
  4. Cebers, 2017, AZD3293: pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer’s disease., J Alzheimers Dis, 55, 1039, 10.3233/JAD-160701 · DOI
  5. Cebers, 2016, Reversible and species-specific depigmentation effects of AZD3293, a BACE inhibitor for the treatment of Alzheimer’s disease, are related to BACE2 inhibition and confined to epidermis and hair., J Prev Alzheimers Dis, 3, 202
  6. Eketjäll, 2016, AZD3293: a novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics., J Alzheimers Dis, 50, 1109, 10.3233/JAD-150834 · DOI
  7. Sims, 2017, Development review of the BACE1 inhibitor lanabecestat (AZD3293/LY3314814)., J Prev Alzheimers Dis, 4, 247
  8. Mohs, 1997, Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope: the Alzheimer’s Disease Cooperative Study., Alzheimer Dis Assoc Disord, 11, S13, 10.1097/00002093-199700112-00003 · DOI
  9. Rosen, 1984, A new rating scale for Alzheimer’s disease., Am J Psychiatry, 141, 1356, 10.1176/ajp.141.11.1356 · DOI · Paper page
  10. Galasko, 1997, An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease: the Alzheimer’s Disease Cooperative Study., Alzheimer Dis Assoc Disord, 11, S33, 10.1097/00002093-199700112-00005 · DOI
  11. Galasko, 2004, Galantamine maintains ability to perform activities of daily living in patients with Alzheimer’s disease., J Am Geriatr Soc, 52, 1070, 10.1111/j.1532-5415.2004.52303.x · DOI
  12. Pfeffer, 1982, Measurement of functional activities in older adults in the community., J Gerontol, 37, 323, 10.1093/geronj/37.3.323 · DOI
  13. Wessels, 2015, A combined measure of cognition and function for clinical trials: the Integrated Alzheimer’s Disease Rating Scale (iADRS)., J Prev Alzheimers Dis, 2, 227
  14. Hughes, 1982, A new clinical scale for the staging of dementia., Br J Psychiatry, 140, 566, 10.1192/bjp.140.6.566 · DOI · Paper page
  15. Cummings, 1997, The Neuropsychiatric Inventory: assessing psychopathology in dementia patients., Neurology, 48, S10, 10.1212/WNL.48.5_Suppl_6.10S · DOI
  16. Folstein, 1975, “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician., J Psychiatr Res, 12, 189, 10.1016/0022-3956(75)90026-6 · DOI · Paper page
  17. Navitsky, 2018, Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale., Alzheimers Dement, 14, 1565, 10.1016/j.jalz.2018.06.1353 · DOI · Paper page
  18. Kennedy, 2016, The BACE1 inhibitor verubecestat (MK-8931) reduces CNS ß-amyloid in animal models and in Alzheimer’s disease patients., Sci Transl Med, 8, 10.1126/scitranslmed.aad9704 · DOI
  19. Hu, 2016, Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling., J Neurochem, 136, 234, 10.1111/jnc.13395 · DOI
  20. Luo, 2001, Mice deficient in BACE1, the Alzheimer’s ß-secretase, have normal phenotype and abolished ß-amyloid generation., Nat Neurosci, 4, 231, 10.1038/85059 · DOI · Paper page
  21. Meakin, 2018, Bace1-dependent amyloid processing regulates hypothalamic leptin sensitivity in obese mice., Sci Rep, 8, 55, 10.1038/s41598-017-18388-6 · DOI · Paper page
  22. Beckmann, 2016, Longitudinal noninvasive magnetic resonance imaging of brain microhemorrhages in BACE inhibitor–treated APP transgenic mice., Neurobiol Aging, 45, 50, 10.1016/j.neurobiolaging.2016.05.009 · DOI

Cited by

Sorted by citations

Metadata

Authors
Wessels, A. M., Tariot, P. N., Zimmer, J. A., Selzler, K. J., Bragg, S. M., Andersen, S. W., Landry, J., Krull, J. H., Downing, A. M., Willis, B. A., Shcherbinin, S., Mullen, J., Barker, P., Schumi, J., Shering, C., Matthews, B. R., Stern, R. A., Vellas, B., Cohen, S., MacSweeney, E., Boada, M., & Sims, J. R.
Affiliations
  • Eli Lilly and Company, Indianapolis, Indiana
  • Banner Alzheimer’s Institute, University of Arizona College of Medicine, Phoenix
  • AstraZeneca, Waltham, Massachusetts, and Gaithersburg, Maryland
  • Alzheimer’s Disease Center, Boston University School of Medicine, Boston, Massachusetts
  • Gérontopôle, Centre Hospitalier Universitaire de Toulouse, Unités Mixtes de Recherche Institut National de la Santé et de la Recherche Médicale 1027, Université Toulouse III–Paul Sabatier, Toulouse, France
  • Toronto Memory Program, Toronto, Ontario, Canada
  • Re:Cognition Health, London, United Kingdom
  • Research Center and Memory Clinic, Fundació Alzheimer Centre Educacional, Institut Català de Neurociències Aplicades, Barcelona–Universitat Internacional de Catalunya, Barcelona, Spain
Venue
JAMA Neurology
Publisher
American Medical Association (AMA)
Published
2020-02-01
Volume
77
Issue
2
Pages
199
ISSN
2168-6149
DOI
10.1001/jamaneurol.2019.3988
PMC
PMC6902191
Cited by
209
References
8
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review